Evidence map›Paper›PMID 41589575›Full record

Trial reportIntegrative cancer therapies

Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Yichao Wang, Lijing Jiao, Zhiwei Chen, Jianfang Xu, Jiaming Che, Hai Huang, Lei Zhang, Xiaoyong Shen, Yi Yang, Tiancheng Zhao and 12 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01441752 (State Administration of Traditional Chinese Medicine of Shanghai), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01441752 phase3completednot on this map

State Administration of Traditional Chinese Medicine of Shanghai

TypeinterventionalSponsorxulingRan2011 to 2015Enrolled349ConditionsNon-small Cell Lung CancerArmsTCM, placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yichao WangDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Lijing JiaoDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Zhiwei ChenShanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, P.R. China.
Jianfang XuDepartment of Oncology, Shanghai Pulmonary Hospital, Tongji University, P.R. China.
Jiaming CheDepartment of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University, P.R. China.
Hai HuangDepartment of Pneumology, Changzheng Hospital, The Naval Medical University, Shanghai, P.R. China.
Lei ZhangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, P.R. China.
Xiaoyong ShenDepartment of Thoracic Surgery, Huadong Hospital, Fudan University, Shanghai, P.R. China.
Yi YangDepartment of Thoracic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, P.R. China.
Tiancheng ZhaoDepartment of Thoracic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, P.R. China.
Jie ZhangDepartment of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, P.R. China.
Di ZhouDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.ORCID 0009-0004-7965-6383
Qin WangDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.ORCID 0000-0002-0851-7106
Jialin YaoDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Wenxiao YangDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Chenbing SunDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Jiaqi LiDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Ling BiDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Rongzhen DingDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Ian GoodfellowDepartment of Pathology, University of Cambridge, UK.
Yabin GongDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.
Ling XuDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China.ORCID 0000-0002-8144-8063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe NALLC trial (NCT01441752) demonstrated that postoperative adjuvant chemotherapy combined with traditional Chinese medicine (TCM) improved the quality of life (QoL) and survival in resected stage Ib-IIIa non-small-cell lung cancer (NSCLC) patients. This report updates disease-free survival (DFS) and other key outcomes.

methodsBetween December 2012 and August 2015, 334 patients were randomized to receive either adjuvant chemotherapy plus traditional Chinese herbal granules (n = 167) or adjuvant chemotherapy plus placebo (n = 167) across 7 centers. Patients continued herbal granules or placebo daily until chemotherapy completion. DFS updates data was conducted in the intention-to-treat (ITT) population.

resultsThe median follow-up was 116.87 months. Median DFS was 71.83 months for the TCM group versus 43.60 months for the control (HR: .86; 95% CI: .64-1.15;

conclusionsAdjuvant chemotherapy combined with TCM showed a potential trend toward improved DFS in early-stage NSCLC patients.

trial registrationThis trial was registered with Clinical. TRIALS: gov (Number: NCT01441752, July 14, 2011).

Indexed as

Carcinoma, Non-Small-Cell LungDrugs, Chinese HerbalLung NeoplasmsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodFemaleHumansMaleMedicine, Chinese TraditionalMiddle AgedQuality of LifeSurvival AnalysisDrugs, Chinese Herbaladjuvant chemotherapydisease-free survivalnon-small cell lung cancersubsequent traditional Chinese medicine treatmenttraditional Chinese medicine

Identifiers

PMID41589575
PMCPMC12847656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.